What are disease modifying therapies (DMTs) and what impact could they have for people living with Parkinson’s?

In this episode, we delve into the evolving world of DMTs, exploring their potential to slow, halt, or even reverse the progression of Parkinson's, and the challenges involved in bringing these therapies to fruition.

We hear from Philippe, who shares his personal journey with the condition and his thoughts on what it means to slow its progression.

Joining him is Kate Trenam, a Senior Director at the global biopharma company UCB, who provides expert insights into current research, global collaboration efforts, and how DMTs could one day change the way Parkinson’s is treated.

We explore the challenges of measuring the effectiveness of DMTs, the importance of global representation in clinical studies, and why continued patient participation in research is critical to progress.

Meet your hosts:

Amelia Hersey is Research Manager at Parkinson's Europe. She has a master's in cognitive neuropsychology and has been involved in the neurodegenerative research world for 15 years.

Anthony Zahra is a broadcaster and journalist with more than 20 years’ experience in radio, digital and podcasting.

For the latest research and information on Parkinson’s, visit the Parkinson's Europe website.

If you like what you’ve heard, please rate and review – it helps make sure others can find us. Keep a lookout for our next episode and until then, take care!

Hosted on Acast. See acast.com/privacy for more information.

Exploring disease modifying therapies for Parkinson’s